skip to Global Navigation Bar skip to main content


homeHome > About Us > Recruitment > News

News

News Content
Daewoong Pharmaceutical’s diabetes treatment, ‘DWP16001,’ approved for clinical test phase 2 in Korea.
Date 2019-05-31 Hit 1566
list
News List
Prev Daewoong Pharmaceutical’s ‘Urusa 300mg’ secured application to ‘prevention of gallbladder stones after gastrectomy’ for the first time in the world.
Next DWN12088, Daewoong Pharmaceutical’s new drug for pulmonary fibrosis, enters global clinical studies phase 1.